Peak Performance Suite

Tesamorelin: Precision reduction for deep belly fat.

You’ve done everything right – the diet, the training, the lifestyle. But the fat around your midsection won’t move, your metabolism feels stuck, and your sharpness isn’t what it used to be. Tesamorelin is built for exactly this picture – and it’s the most clinically validated peptide in its class.

Protocols start at $250/month after a $599 Foundational Assessment. See full pricing

Book a Peptide Consult
Peak Performance pathway › Tesamorelin See every Peak Performance option

Does This Sound Like You?

Tesamorelin is best suited for men and women over 35 who are dealing with stubborn visceral fat, early metabolic dysfunction, or early cognitive concerns that have already been medically evaluated – and who are ready for the most advanced peptide protocol available.

You may be a strong candidate if you:

  • Carry persistent fat around your midsection that hasn’t responded to diet or exercise
  • Have been told your metabolic markers – triglycerides, blood sugar, inflammation – are trending in the wrong direction
  • Are noticing early changes in memory, focus, or mental sharpness
  • Feel like your metabolism is working against you despite doing everything right
  • Want to address visceral fat as a genuine health risk, not just an aesthetic concern
  • Are looking for the most clinically validated, physician-supervised peptide protocol available

Tesamorelin can be combined with BHRT depending on your full clinical picture. Our provider team will evaluate your labs, history, and goals before any protocol is built – nothing is prescribed without the complete picture.

Our Foundational Assessment is where it starts. It gives us – and you – everything we need.

tesamorelin
tesamorelin

This Isn't Stubborn Fat. It's a Metabolic Signal.

There’s a specific type of fat that sits deep in the abdomen – surrounding your internal organs, driving inflammation, and quietly contributing to insulin resistance, cardiovascular risk, and metabolic dysfunction.1 Modest weight loss actually tends to shrink visceral fat preferentially, but it can be hard to reach and hold that loss. You can be lean everywhere else2 and still carry it.

That fat has a name: visceral adipose tissue. And Tesamorelin is the only peptide carrying an FDA approval specifically for reducing it — an approval granted for adults with HIV-associated lipodystrophy.34

How Tesamorelin Works

Tesamorelin is a GHRH analog – it prompts your pituitary to release more of your own growth hormone, which declines steadily with age in adults. In clinical trials, this reduced visceral fat without significantly reducing the fat under the skin.56 The result isn’t just a change in how you look. It’s a meaningful shift in your metabolic health from the inside out.

This is the most advanced growth hormone optimization protocol offered at YoungerMeMD – and it’s built for patients who want more than maintenance.

What Our Patients Notice

Tesamorelin is administered five out of seven nights via subcutaneous injection. Most patients begin noticing meaningful changes within 6-12 weeks. Here’s what patients commonly report.

tesamorelin

Belly fat that finally starts to move

Visceral fat is metabolically stubborn by nature. In placebo-controlled trials in adults with HIV-associated abdominal fat, tesamorelin reduced visceral adipose tissue by about 15% relative to placebo over 26 weeks, and the reduction was maintained through 52 weeks with continued use. A 12-month trial in abdominally obese adults without HIV who had reduced growth hormone secretion also found a significant reduction.67

A metabolism that feels like it’s working again

In trials, tesamorelin lowered triglycerides, and in obese adults without HIV it also lowered C-reactive protein without worsening blood sugar.78 Patients describe a shift from feeling metabolically stuck to feeling like their body is actually cooperating again.

Sharper focus and better memory

In a 20-week randomized trial published in Archives of Neurology (now JAMA Neurology), tesamorelin improved executive function in older adults with and without mild cognitive impairment, with a non-significant trend for verbal memory.9 For patients noticing early cognitive changes, this is one of the most compelling aspects of the protocol.

Better recovery and deeper sleep

Growth hormone release is closely tied to deep sleep. Tesamorelin has not been studied for sleep or recovery, and in a controlled study of a related GHRH analog in older adults, self-rated sleep quality did not change. Some patients still report better rest.1011

Holding on to more lean muscle

In a placebo-controlled trial in adults with HIV-associated abdominal fat, lean body mass improved with tesamorelin, and in a trial in older adults it reduced percent body fat.129

Long-term protection that goes beyond how you look.

Visceral fat is an independent risk marker for cardiovascular disease and type 2 diabetes, so reducing it is a health goal, not a cosmetic one. Whether lowering it with tesamorelin reduces long-term cardiovascular events has not yet been established.113

Pharmaceutical-Grade. Every Time.

Every Tesamorelin prescription at YoungerMeMD is sourced exclusively from fully vetted, state-licensed 503A compounding pharmacies. Our peptides are never labeled “for research purposes.” They are compounded for prescription clinical use only – dispensed under physician supervision, prepared to strict standards for sterility, potency, and quality control.

Your metabolic health deserves pharmaceutical-grade precision. That is the only standard we use.

Mitochondrial health
tesamorelin

Safety & Considerations

Tesamorelin was generally well tolerated in clinical trials. The most common side effects were joint pain, injection-site redness or itching, pain in the arms or legs, swelling from fluid retention, and muscle aches. It can also raise blood sugar, so glucose should be checked before and during treatment.13

Tesamorelin must not be used in people with active cancer, and any past cancer should be inactive with treatment complete before starting. It is also not used in people with pituitary or hypothalamic disorders (for example after pituitary surgery or head irradiation), and it should not be used during pregnancy or breastfeeding.13 Always inform your provider about all current medications, supplements, and existing health conditions before starting any protocol.

Consistent sleep, regular physical activity, stress management, and balanced nutrition support your treatment – deep sleep and body fat in particular are strong influences on natural growth hormone secretion.14

The YoungerMeMD Tesamorelin Program

The most clinically validated visceral fat reduction and metabolic optimization protocol available – physician-supervised and built around your biology.

STEP 1

Foundational Assessment

$599

A complete assessment of:

  • Visceral fat status and body composition markers
  • Metabolic panel including triglycerides, blood sugar, and inflammatory markers
  • Growth hormone and IGF-1 baseline levels
  • Hormonal and metabolic factors influencing body composition
  • Cognitive health indicators and early decline screening
  • Current medications, supplements, and contraindications

This establishes which Tesamorelin protocol is right for your picture and determines whether you begin at the low or high dose based on your clinical presentation.

Book Your Assessment
STEP 2

Peptide Membership

$279/month

Your foundational membership provides continuous support and medical oversight.

Your Membership Includes:

  • Personalized peptide programming
  • Ongoing biological and functional monitoring
  • Direct clinician messaging
  • Protocol optimization based on response
  • Exclusive pricing on peptide cycles
STEP 3

Tesamorelin Protocol

We start every patient at the low dose and assess response before making any adjustments. Most patients achieve their goals at the low dose – escalation is guided by your biology, not a default.

Low Dose Protocol – $250/month

The starting protocol for all Tesamorelin patients. Administered five out of seven nights via subcutaneous injection. For patients who respond well at this level, this remains the ongoing protocol.

High Dose Protocol – $350/month

For patients whose results plateau or who don’t achieve satisfactory progress at the low dose. Administered five out of seven nights. Escalation is always provider-directed based on clinical response monitoring.

Either protocol is deemed an ongoing treatment. Your provider team monitors response and determines the appropriate dose level based on your labs, symptoms, and body composition changes over time.

Is Tesamorelin FDA-approved?

Yes – and that matters. Tesamorelin is the only GHRH analog with FDA approval specifically for visceral fat reduction — granted for adults with HIV-associated lipodystrophy — giving it one of the most well-documented clinical safety profiles among all peptides available today.63 At YoungerMeMD, it is used off-label for adult metabolic and longevity optimization under the direct supervision of Dr. Varano and his provider team.

Tesamorelin is administered via subcutaneous injection – a small, fine-needle injection given at home five out of seven nights. Our care team provides full training and is available for support as you get started.

The published trials of tesamorelin used daily dosing. Our five-out-of-seven schedule is a clinical choice intended to avoid continuous stimulation; it has not yet been compared with daily dosing in published studies.4

We start every patient on the low dose protocol and monitor response over the first several weeks. For patients who respond well at the lower dose, there is no need to escalate. For patients who don’t achieve satisfactory results at the lower dose, we move to the high dose protocol. This approach minimizes unnecessary exposure and lets your biology guide the escalation decision rather than starting everyone at the ceiling.

Many patients notice early improvements in energy and sleep within the first few weeks. Meaningful changes in body composition and visceral fat reduction typically emerge over 6-12 weeks, with the most significant results at the 3-6 month mark with consistent use.124

Yes. A 20-week randomized trial published in Archives of Neurology (now JAMA Neurology) found improved executive function in older adults on tesamorelin, with a trend toward better verbal memory – making it one of the few peptides9 with published cognitive outcome data. For patients with early cognitive concerns, this is a meaningful part of the protocol.

Absolutely. Tesamorelin fits naturally within a broader optimization protocol and can be incorporated alongside BHRT or other peptide programs depending on your goals and where you are in your health journey. Every protocol is built individually by our provider team – nothing is stacked without clinical justification.

Tesamorelin is offered through YoungerMeMD’s membership-based model, which operates outside of traditional insurance. Your membership includes physician oversight, ongoing protocol management, and the kind of personalized attention that insurance-based care isn’t designed to provide.

Questions We Hear All the Time

If You Want the Most Advanced Protocol, This Is It.

Tesamorelin isn’t a starting point. It’s where patients who are serious about metabolic health, body composition, and cognitive longevity arrive when they’re ready to go further than anything else has taken them.

It starts with a conversation and the right labs. From there, our provider team builds a protocol around your specific picture – not a template, not a guess.

Book Your Assessment
Tesamorelin Within Your Peptide Journey

Pairs Well With Tesamorelin

Visceral fat and metabolic dysfunction rarely exist in isolation. These protocols address the systemic layers that determine how completely and how durably Tesamorelin's results take hold — and what becomes possible once the metabolic environment shifts.

Most Paired

Hormone Optimization

Sex hormones shape body composition: in a controlled study of men, estrogen deficiency mainly increased body fat, while testosterone deficiency reduced lean mass and strength.15 Tesamorelin addresses the growth hormone layer, while hormone optimization addresses the sex hormone layer that shapes the metabolic environment it works in.

Best for: patients over 40 whose visceral fat and metabolic decline have a clear hormonal component alongside GH deficiency

Learn about Hormone Health
Metabolic Foundation

DefendMe — Thymosin Alpha-1

Excess visceral fat goes along with lower natural growth hormone production and low-grade inflammation. Thymosin Alpha-1 is an immune-modulating peptide; it has not yet been studied as a treatment for visceral fat.148

Best for: patients with elevated CRP, chronic inflammation, or autoimmune history complicating visceral fat reduction

Learn about DefendMe
Cognitive Layer

CognitiveMe — Semax

Tesamorelin has published trial data showing improved executive function in older adults. Semax works through a different pathway: in rat studies it increased BDNF, a growth factor involved in neuroplasticity. The combination has not yet been studied in people.916

Best for: patients seeking both visceral fat reduction and meaningful cognitive restoration as primary goals

Learn about CognitiveMe
Gut-Metabolic Axis

Gut Restoration — BPC-157 + KPV

Gut health and inflammation are being studied as possible contributors to insulin resistance and visceral fat. BPC-157 and KPV have mainly been studied in animal and laboratory models, and they have not yet been shown to improve tesamorelin’s results in people.

Best for: patients with GI symptoms, metabolic dysfunction, or inflammatory markers suggesting a gut-driven metabolic component

Learn about Gut Restoration
Ready to build the most complete metabolic protocol available? Your Tesamorelin protocol is always built around your specific picture. Our provider team will identify which pairings will accelerate your results and what addressing the underlying metabolic environment will do for everything else you're working toward.
Book Your Assessment

References

  1. Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019. PMID 31301983 · doi:10.1016/S2213-8587(19)30084-1↩
  2. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes (Lond) 2008. PMID 18180786 · doi:10.1038/sj.ijo.0803761↩
  3. U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin for injection) prescribing information, BLA022505 (openFDA drug label, effective 20260729). openFDA Drug Label API 2026. Source↩
  4. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. PMID 18057338 · doi:10.1056/NEJMoa072375↩
  5. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991. PMID 1939523 · doi:10.1210/jcem-73-5-1081↩
  6. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010. PMID 20554713 · doi:10.1210/jc.2010-0490↩
  7. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab 2012. PMID 23015655 · PMC3513535 · doi:10.1210/jc.2012-2794↩
  8. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis 2012. PMID 22495074 · PMC3348954 · doi:10.1093/cid/cis251↩
  9. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol 2012. PMID 22869065 · PMC3764914 · doi:10.1001/archneurol.2012.1970↩
  10. Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA 2000. PMID 10938176 · doi:10.1001/jama.284.7.861↩
  11. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997. PMID 9141536 · doi:10.1210/jcem.82.5.3943↩
  12. Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS 2005. PMID 16052083 · doi:10.1097/01.aids.0000180099.35146.30↩
  13. U.S. Food and Drug Administration. EGRIFTA SV (tesamorelin for injection) prescribing information, BLA022505 (openFDA drug label, effective 20260729). openFDA Drug Label API 2026. Source↩
  14. Veldhuis JD, Iranmanesh A. Physiological regulation of the human growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 1996. PMID 9085516 · doi:10.1093/sleep/19.suppl_10.s221↩
  15. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013. PMID 24024838 · PMC4142768 · doi:10.1056/NEJMoa1206168↩
  16. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006. PMID 16996037 · doi:10.1016/j.brainres.2006.07.108↩
Medically reviewed by Kenneth Varano, D.O., Pennsylvania osteopathic physician license OS009028L (Pennsylvania State Board of Osteopathic Medicine) · Last reviewed Medical Director, YoungerMeMD · Board certified in Integrative Medicine (ABOIM) and Family Practice, and an Advanced Fellow in Anti-Aging, Functional and Nutritional Medicine (A4M).